- Record: found
- Abstract: not found
- Article: not found
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K Abou-Alfa ,
Vaibhav Sahai ,
Antoine Hollebecque ,
Gina Vaccaro ,
Davide Melisi ,
Raed Al-Rajabi ,
Andrew S Paulson ,
Mitesh J Borad ,
David Gallinson ,
Adrian G Murphy ,
Do-Youn Oh ,
Efrat Dotan ,
Daniel V Catenacci ,
Eric Van Cutsem ,
Tao Ji ,
Christine F Lihou ,
Huiling Zhen ,
Luis Féliz ,
Arndt Vogel
March 2020
March 2020
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d89363e324">Fibroblast growth factor receptor (FGFR) 2 gene alterations
are involved in the pathogenesis
of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1,
2, and 3. This study evaluated the safety and antitumour activity of pemigatinib in
patients with previously treated, locally advanced or metastatic cholangiocarcinoma
with and without FGFR2 fusions or rearrangements.
</p>